L Veneroni1, L Boschetti2, F Barretta3, C A Clerici4,5, F Simonetti2, E Schiavello2, V Biassoni2, F Spreafico2, L Gandola6, E Pecori6, B Diletto6, G Poggi7, F Gariboldi8, R Sensi8, M Massimino2. 1. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy. laura.veneroni@istitutotumori.mi.it. 2. Pediatric Oncology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Via G. Venezian 1, 20133, Milan, Italy. 3. Unit of Clinical Epidemiology and Trial Organization, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 4. Clinical Psychology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 5. Department of Oncology and Hematology, University of Milan, Milan, Italy. 6. Pediatric Radiotherapy Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. 7. Aquired Brain Injury Unit, Scientific Institute, IRCCS Eugenio Medea, Milan, Italy. 8. Unit of Palliative care, Pain Therapies and Rehabilitation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Abstract
PURPOSE: An intensive therapeutic strategy for metastatic medulloblastoma was launched in 1998 in our Institution. The aim of this study was to examine the long-term quality of life (QoL) in survivor patients at least 3 years after the end of the treatment. METHODS: Patients were asked to complete self-administered QoL questionnaires. An index of physical impairment (IPI) was scored (range 0-100; the lower the score the better) based on clinical objective observations. Patients were divided into two groups (lower IPI group, and higher IPI group) and descriptively compared accordingly. RESULTS: The study was completed by 25/33 eligible patients. Despite patients with a higher IPI reported worse perceived health condition, they had better emotional and psychological scores than those with a lower IPI in all QoL questionnaires. CONCLUSION: In our sample, patients with more severe objective and perceived physical impairments reported a better psychosocial QoL, possibly because the greater attention paid to them by society and family contributes to a better adjustment in long-term survivors. On this base, it should be recommended that all survivors receive a strong support as the most impaired patients.
PURPOSE: An intensive therapeutic strategy for metastatic medulloblastoma was launched in 1998 in our Institution. The aim of this study was to examine the long-term quality of life (QoL) in survivor patients at least 3 years after the end of the treatment. METHODS:Patients were asked to complete self-administered QoL questionnaires. An index of physical impairment (IPI) was scored (range 0-100; the lower the score the better) based on clinical objective observations. Patients were divided into two groups (lower IPI group, and higher IPI group) and descriptively compared accordingly. RESULTS: The study was completed by 25/33 eligible patients. Despite patients with a higher IPI reported worse perceived health condition, they had better emotional and psychological scores than those with a lower IPI in all QoL questionnaires. CONCLUSION: In our sample, patients with more severe objective and perceived physical impairments reported a better psychosocial QoL, possibly because the greater attention paid to them by society and family contributes to a better adjustment in long-term survivors. On this base, it should be recommended that all survivors receive a strong support as the most impaired patients.
Entities:
Keywords:
HART strategy; Metastatic medulloblastoma; Quality of life; Survivors
Authors: Jennifer A Limond; Kim S Bull; Gabriele Calaminus; Colin R Kennedy; Helen A Spoudeas; Mathilde P Chevignard Journal: Eur J Paediatr Neurol Date: 2014-12-17 Impact factor: 3.140
Authors: Gemma Gatta; Giulia Zigon; Riccardo Capocaccia; Jan Willem Coebergh; Emmanuel Desandes; Peter Kaatsch; Guido Pastore; Rafael Peris-Bonet; Charles A Stiller Journal: Eur J Cancer Date: 2009-02-21 Impact factor: 9.162
Authors: Tara M Brinkman; Wilburn E Reddick; Joshua Luxton; John O Glass; Noah D Sabin; Deo Kumar Srivastava; Leslie L Robison; Melissa M Hudson; Kevin R Krull Journal: Neuro Oncol Date: 2012-09 Impact factor: 12.300
Authors: Iska Moxon-Emre; Eric Bouffet; Michael D Taylor; Normand Laperriere; Nadia Scantlebury; Nicole Law; Brenda J Spiegler; David Malkin; Laura Janzen; Donald Mabbott Journal: J Clin Oncol Date: 2014-02-10 Impact factor: 44.544
Authors: Mikaela Doig; Eva Bezak; Nayana Parange; Peter Gorayski; Victoria Bedford; Michala Short Journal: Cancers (Basel) Date: 2022-08-15 Impact factor: 6.575
Authors: Cynthia B de Medeiros; Iska Moxon-Emre; Nadia Scantlebury; David Malkin; Vijay Ramaswamy; Alexandra Decker; Nicole Law; Toshihiro Kumabe; Jeffrey Leonard; Josh Rubin; Shin Jung; Seung-Ki Kim; Nalin Gupta; William Weiss; Claudia C Faria; Rajeev Vibhakar; Lucie Lafay-Cousin; Jennifer Chan; Johan M Kros; Laura Janzen; Michael D Taylor; Eric Bouffet; Donald J Mabbott Journal: Cancer Med Date: 2019-11-21 Impact factor: 4.452
Authors: Simon Bailey; Nicolas André; Lorenza Gandola; Maura Massimino; Stefan Rutkowski; Steven C Clifford Journal: Cancers (Basel) Date: 2022-01-13 Impact factor: 6.575